Griseofulvin

Griseofulvin is an orally active antifungal antibiotic with antitumor activity. Griseofulvin induces apoptosis and G2/M cell cycle arrest in cancer cells. Griseofulvin also has cardiovascular modulatory activity, reducing angina pectoris, relieving hand artery spasm associated with onychomycosis, and peripheral vascular diseases such as shoulder-hand syndrome^{[1][2][3][4][5][6]}. In Vitro:The minimum inhibitory concentrations (MICs) of Griseofulvin against T. rubrum, T tonsurans, and T mentagrophytes in planktonic and biofilm growth were 0.0078-0.0156 μg/ml, 1-4 μg/mL, and 1-4 μg/mL, respectively^[1].
Griseofulvin inhibits the growth of KMS 18, OPM-2, RPMI-8226, U-266, MPC-11, Primary CLL cells, Raji, RAW 264,7, Oci Ly 8 Lam 53, SU DHL 4 cell lines with IC₅₀ values ​​of 9 μM, 45 μM, 26 μM, 18 μM, 44 μM, 80 μM, 33 μM, 28 μM, 30 μM and 22 μM^[2].
Griseofulvin (10-100 µM; 72 h) inhibits the viability of human myeloma cells in a concentration-dependent manner^[2].
Griseofulvin (0-50 µM; 30 h) dose-dependently induces apoptosis in colon cancer cells (COLO 205 and HT 29), liver cancer cells (Hep G2 and Hep 3B) and leukemia cells HL 60^[6].
Griseofulvin (0-20 µM; 24 h) induces abnormal microtubule polymerization in HT 29 cells^[6].
Griseofulvin (5-60 µM; 24 h) induces apoptosis at lower doses^[6].
In Vivo:Griseofulvin (0.5-3 mg/kg in crossbred dogs; 2 and 5 mg/kg in rats; i.v.) increases ventricular contractility and coronary blood flow in dogs and rats^[5].
Griseofulvin (50 mg/kg; i.p.; 3 injections per week for 6 weeks) reduces tumor volume in COLO 205 xenograft mice^[6].